Orally Inhaled Bronchodilators to 2022

Chart_Collage_160  Published April 2015  •  Catalog no. HBD654F  •  Price US $2,850

Asthma and COPD continue to be a health segments that present significant challenges to patients and the caregiver community. Patient adherence with prescribing instructions and treatment protocols remains sub-optimal across all patient categories, but particularly for the young and the elderly. This has led to significant interest on the part of device and combination product providers directed toward the development easier-to-use inhalers. Because they relax smooth muscles in the airways, bronchodilators are an indispensable tool for the treatment of upper respiratory diseases. The market entry of combination drug inhalers that deliver a bronchodilator and a corticosteroid from the same inhaler are providing important options for both clinicians and patients.

Bar_Graph Orally Inhaled Bronchodilators to 2022 Report Prospectus (Download PDF)

Blue document Orally Inhaled Bronchodilators to 2022 Report Order Form (Download PDF)


• Analyzes the market for bronchodilator drugs delivered via oral inhalers
• Assesses inhalation device technology for delivering bronchodilators orally, and evaluates product technology issues and evolving market factors
• Provides detailed assessments of orally inhaled bronchodilator product segments, growth prospects and market potential
• Provides market data and forecasts for orally inhaled bronchodilators to 2022
• Profiles inhaled drug product market participants, their technology, product development activity, and business strategies
• Evaluates the impact of economic, technology, and regulatory factors on inhaled drug companies and their alliance partners

Summary of Contents

Executive Summary

Orally Inhaled Corticosteroid Market Overview

The Upper Respiratory Therapeutics Marketspace
Therapeutic Targets for Orally Inhaled Bronchodilators
Competing Drug Treatments
Demand Drivers
Technology Factors
Competitive Landscape

Asthma Market Risks and Opportunities

Global Patient Demographics
Regional Market Drivers
Pediatric Asthma –the Growing Therapeutic Need

Inhaler Technologies for Delivering Bonchodilators

Dry Powder Inhalers
DPI Formulation Technology
Characteristics and Parameters
DPI Excipients and Packaging
Metered Dose Inhalers
MDI Device Selection Criteria
Ease-of-Use Factors

Inhaled Bronchodilators – Product Analysis, Market Data & Forecasts

Albuterol, Proventil HFA (MDI)
Albuterol, Ventolin HFA (MDI)
Albuterol, ProAir HFA (MDI)
Albuterol, Accuneb (Nebulizer)
Generic Albuterol (Nebulizer)
Albuterol/Ipratropium (Combuvent) Combination Drug Inhaler (MDI)
Albuterol/Ipratropium (Duoneb) Combination Drug Solution (Nebulizer)
Generic Albuterol/Ipratropium Combination Drug Solution (Nebulizer)
Fluticasone/Vilanterol (Breo Ellipta) Combination Drug Inhaler (DPI) Fluticasone/Salmeterol (Advair HFA) Combination Drug Inhaler (MDI)
Fluticasone/Salmeterol (Advair Diskus) Combination Drug Inhaler (DPI)
Formoterol, Foradil (DPI)
Formoterol, Perforomist (Nebulizer)
Formoterol/Mometasone (Dulera) Combination Drug Inhaler (MDI)
Ipratropium, Atrovent HFA (MDI)
Generic Ipratropium (Nebulizer)
Levalbuterol, Xopenex (Nebulizer)
Generic Levalbuterol (Nebulizer)
Levalbuterol, Xopenex HFA( MDI)
Salmeterol, Serevent (DPI)
Tiotropium, Spiriva (DPI)
Tiotropium, Spiriva Respimat (MDI)
Umeclidinium, Incruse Ellipta (DPI)
Umeclidinium/Vilanterol (Anoro) Combination Drug Inhaler (DPI)

Market Factors

Regulatory Issues
Patient Compliance
Prescribing Trends
Healthcare Economics
Regional Market Factors
Connected Devices

Market Sector Company Profiles

Comments or questions?

* indicates required field